{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:01:56Z","timestamp":1791414116753,"version":"4.3.3"},"reference-count":41,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority","award":["HHSO100201300011C"],"award-info":[{"award-number":["HHSO100201300011C"]}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,3,15]]},"abstract":"<jats:p>Antibiotics are the current standard-of-care treatment for uncomplicated urinary tract infections (uUTIs). However, increasing rates of bacterial antibiotic resistance necessitate novel therapeutic options.<\/jats:p>","DOI":"10.1128\/aac.01492-21","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T18:19:59Z","timestamp":1641233999000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":45,"title":["Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections"],"prefix":"10.1128","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4211-8261","authenticated-orcid":true,"given":"Nicole E.","family":"Scangarella-Oman","sequence":"first","affiliation":[{"name":"Research and Development, GlaxoSmithKline plc, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hossain","sequence":"additional","affiliation":[{"name":"Research and Development, GlaxoSmithKline plc, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6769-7541","authenticated-orcid":true,"given":"Jennifer L.","family":"Hoover","sequence":"additional","affiliation":[{"name":"Research and Development, GlaxoSmithKline plc, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R.","family":"Perry","sequence":"additional","affiliation":[{"name":"Research and Development, GlaxoSmithKline plc, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Tiffany","sequence":"additional","affiliation":[{"name":"Research and Development, GlaxoSmithKline plc, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4788-6051","authenticated-orcid":true,"given":"Aline","family":"Barth","sequence":"additional","affiliation":[{"name":"Research and Development, GlaxoSmithKline plc, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne F.","family":"Dumont","sequence":"additional","affiliation":[{"name":"Research and Development, GlaxoSmithKline plc, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13698"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2017.1359543"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3432"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.UTI-0002-2012"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12427"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1586\/eri.11.77"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00199-20"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv043"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7656752"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00862-20"},{"key":"e_1_3_2_13_2","volume-title":"WHO global strategy for containment of antimicrobial resistance.","author":"World Health Organization.","year":"2001","unstructured":"World Health Organization. 2001. WHO global strategy for containment of antimicrobial resistance. World Health Organization, Geneva, Switzerland. https:\/\/www.who.int\/drugresistance\/WHO_Global_Strategy_English.pdf."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00315"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09197"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02820-15"},{"key":"e_1_3_2_17_2","unstructured":"Mushtaq S Vickers A Sadouki Z Cole M Fifer H Donascimento V Day M De Pinna E Jenkins C Godbole G Woodford N. 2019. In vitro activities of gepotidacin a novel triazaacenaphthylene and topoisomerase IV DNA gyrase inhibitor against Gram-negative bacteria and Staphylococcus saprophyticus poster P1849. Abstr 29th ECCMID Amsterdam The Netherlands."},{"key":"e_1_3_2_18_2","unstructured":"ClinicalTrials.gov. 2019. NCT04020341: a study to evaluate efficacy and safety of gepotidacin in the treatment of uncomplicated urinary tract infection (UTI). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04020341."},{"key":"e_1_3_2_19_2","unstructured":"ClinicalTrials.gov. 2020. NCT04187144: comparative study to evaluate efficacy and safety of gepotidacin to nitrofurantoin in treatment of uncomplicated urinary tract infection (UTI). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04187144."},{"key":"e_1_3_2_20_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute.","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed, M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02307-18"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0639"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00067-15"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007457"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001042"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00086-19"},{"key":"e_1_3_2_27_2","unstructured":"Hossain M Tiffany CA McDonald M Dumont EF. 2014. Safety and pharmacokinetics of repeat escalating oral doses of GSK2140944: a novel bacterial topoisomerase inhibitor poster F-276. Abstr 54th Intersci Conf Antimicrob Agents Chemother Washington DC."},{"key":"e_1_3_2_28_2","volume-title":"Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products (EMA\/CHMP\/594085\/2015).","author":"European Medicines Agency.","year":"2016","unstructured":"European Medicines Agency. 2016. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products (EMA\/CHMP\/594085\/2015). European Medicines Agency, London, United Kingdom. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-use-pharmacokinetics-pharmacodynamics-development-antimicrobial-medicinal-products_en.pdf."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2013.06.010"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00182-11"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00122-21"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00115-16"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12448"},{"key":"e_1_3_2_34_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute.","year":"2021","unstructured":"Clinical and Laboratory Standards Institute. 2021. Performance standards for antimicrobial susceptibility testing, 31st ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"31"},{"key":"e_1_3_2_35_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2020. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_10.0_Breakpoint_Tables.pdf."},{"key":"e_1_3_2_36_2","unstructured":"ClinicalTrials.gov. 2018. NCT02853435. To assess bioavailability food effect and pharmacokinetics of gepotidacin tablets: a phase I single-dose 2 part study in healthy subjects. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02853435."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","unstructured":"Barth A Hossain M Brimhall DB Perry CR Tiffany CA Xu S Dumont EF. 2022. Pharmacokinetics of oral formulations of gepotidacin (GSK2140944) a triazaacenaphthylene bacterial type II topoisomerase inhibitor in healthy adult and adolescent participants. Antimicrob Agents Chemother 66:e01263-21. doi:10.1128\/AAC.01263-21.","DOI":"10.1128\/AAC.01263-21"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.807"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.913"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2015.1112933"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","unstructured":"Scangarella-Oman NE Hossain M Hoover JL Perry CR Tiffany C Gardiner D Dumont EF. 2021. Dose selection for phase 3 studies evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urinary tract infections abstr 478. Abstr 31st ECCMID.","DOI":"10.1128\/aac.01492-21"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","unstructured":"Zimmerman EI Dumont E Perry C Tiffany C Scangarella-Oman N Raychaudhuri A Hossain M. 2019. Plasma and urine pharmacokinetic analysis of gepotidacin (GSK2140944) following BID oral dosing in a phase IIa study for treatment of uncomplicated urinary tract infections poster 1480. Abstr IDWeek 2019 Washington DC.","DOI":"10.1093\/ofid\/ofz360.1344"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01492-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01492-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T15:04:44Z","timestamp":1647356684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01492-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,15]]}},"alternative-id":["10.1128\/aac.01492-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.01492-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"assertion":[{"value":"2022-03-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01492-21"}}